InflaRx N : 20240425_Minutes 2024 AGM - InflaRx NV_signed
MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS INFLARX N.V. APRIL 25, 2024 Minutes...
Stay updated with breaking news from Thomas Taapken. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS INFLARX N.V. APRIL 25, 2024 Minutes...
Jena, Germany, November 1, 2023 - InflaRx N.V. , a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today financial results...
Single ascending dose (SAD) Phase I data confirm best-in-class potential of orally available C5aR inhibitor INF904; multiple ascending dose (MAD) ...
10.08.2023 - • Quarter highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab) in the United States • Oral C5aR inhibitor INF904 progressing in single ascending dose (SAD) and multiple ascending ...
/PRNewswire/ -- Today, the annual general meeting of 2023 was held in SciBase Holding AB (publ) (the "Company" or "SciBase"). Below follows a summary of the...